Thomas K. Equels, CEO & President at AIM ImmunoTech Inc. (AIM), bought 22,000 shares at $0.22 ($5K) on 2026-09-15, disclosed to the SEC on 2026-09-16.
Open-market purchase of $5k AIM by CEO & President. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.
| Filing → |
| AIM | BUY | 2026-09-15 | $1K | — | Filing → |
| AIM | BUY | 2025-06-16 | $824 | — | Filing → |
| AIM | BUY | 2025-06-13 | $896 | — | Filing → |